Here’s my take on incorporating the available evidence to select the right patients for HIV treatment with long-acting injectable cabotegravir plus rilpivirine.
In this commentary, I share the factors I consider when deciding whether or not to recommend use of the optional 4-week oral lead-in before initiating long-acting cabotegravir plus rilpivirine injections and my thoughts on every-month vs every-2-month dosing.
To extend long-acting PrEP to all potential candidates, we must improve our ability to reach individuals wherever they routinely access health services in the community. Here are my thoughts on the barriers we will need to address as we look to the future and the potential for bringing long-acting PrEP even closer to individuals who would benefit.
Here is my take on important factors related to the use of long-acting HIV therapies in women, including key findings from several recent studies examining women’s preferences for oral vs long-acting injectable HIV treatment and prevention modalities.
In this commentary, I share my thoughts on why it is important that we strive to overcome the barrier of resistance to change among healthcare professionals when it comes to implementing long-acting HIV treatment and prevention strategies for appropriate individuals who have long awaited these options.
In this commentary, I share my thoughts on a new option emerging in the realm of long-acting HIV care with potential application to a range of treatment and prevention settings.